Related Experiment Videos
Helicobacter pylori infection--current treatment practice
H H Xia1, B C Yu Wong, N J Talley
1Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China. hhxxia@hku.hk.
Expert Opinion on Pharmacotherapy
|May 5, 2001
Summary
Helicobacter pylori (H. pylori) eradication therapy effectively treats gastritis and ulcers. However, antibiotic resistance and doctor beliefs can impact treatment success, necessitating careful consideration of regimens and indications.
Area of Science:
- Gastroenterology
- Infectious Diseases
- Pharmacology
Background:
- Helicobacter pylori infection is highly prevalent globally, a primary cause of gastritis, peptic ulcers, and gastric cancer.
- Eradication therapy for H. pylori has been standard clinical practice for over 15 years.
- Established indications for eradication include peptic ulcer disease and gastric MALToma.
Purpose of the Study:
- To review current H. pylori eradication therapies.
- To discuss factors influencing treatment efficacy, including antibiotic resistance and physician beliefs.
- To highlight controversies in the application of eradication therapy for various conditions.
Main Methods:
- Review of established H. pylori eradication regimens.
- Analysis of factors affecting treatment outcomes, such as antibiotic resistance and drug dosage.
- Discussion of clinical practice guidelines and areas of ongoing debate.
Main Results:
- Standard regimens like bismuth-based and proton-pump inhibitor (PPI)-based triple therapies achieve >80% eradication rates.
- H. pylori resistance to metronidazole and clarithromycin can reduce efficacy, though some regimens show promise.
- Antibiotic dose, treatment duration, and physician beliefs significantly influence clinical outcomes.
Conclusions:
- H. pylori eradication is crucial for managing specific gastrointestinal conditions.
- Addressing antibiotic resistance and standardizing treatment protocols are key to improving efficacy.
- Further research and consensus are needed for controversial indications like non-ulcer dyspepsia and GERD.